This cohort study provided evidence supporting the association of tirzepatide treatment, compared to GLP-1 receptor agonists, with lower hazards of all-cause mortality and adverse CV or kidney events through a head-to-head comparison in patients with type 2 diabetes, Vin-Cent Wu, MD, PhD, attending physician in the department of internal medicine at National Taiwan University Hospital, and colleagues wrote These insights advocate for the integration of tirzepatide into therapeutic strategies for managing type 2 diabetes and highlight its potential to enhance current clinical practice. Wu and colleagues analyzed data from the TriNetX U.S
While they contain the same active ingredient, these medications differ significantly in safety, regulation, cost, and reliability
doi: 10.3389/fpsyt.2026.1766770 Received 13 December 2025 Revised 13 February 2026 Accepted 18 February 2026 Published 10 March 2026 Volume 17 - 2026 Edited by Yi-lang Tang, United States Department of Veterans Affairs, United States Reviewed by Ming-Fen Ho, Mayo Clinic, United States Aristea Psilopanagioti, University of Patras, Greece Updates Copyright 2026 Abegaz, Ahmed, Bhagavathula and Frietze
(2023) Anti-obesity medication use for adolescent metabolic and bariatric surgery patients: a systematic literature review